Capmatinib Triggers Responses in NSCLC.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-148
Abstract: A phase II trial of the MET inhibitor capmatinib found that 72% of treatment-naïve patients responded to the drug, whereas the response rate for previously treated patients was 39.1%. The drug's side effects include peripheral… read more here.
Keywords: triggers responses; capmatinib triggers; responses nsclc; capmatinib ... See more keywords